Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"
关注蓝鸟生物；交易员流传未经证实的传言，暗示 “Lyfgenia是有望在25财年初获得NTAP称号的8种新疗法之一，股价飙升。HHS强调支持SCD疗法的获取，这使人们毫不怀疑新疗法是否符合资格”